{"id":1000658,"date":"2026-09-04T08:17:08","date_gmt":"2026-09-04T12:17:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/"},"modified":"2026-09-04T08:17:08","modified_gmt":"2026-09-04T12:17:08","slug":"tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/","title":{"rendered":"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CARLSBAD, Calif.<\/span>, Sept. 4, 2026<\/span> \/PRNewswire\/ —\u00a0Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC).<\/p>\n

\n Conference Call and Webcast Information<\/b>\n <\/p>\n

TYRA is hosting a conference call and webcast on September 9, 2026, at 8:00 am ET. Participants may access a live webcast of the call and the associated slide presentation on the “For Investors” page of the TYRA website\u00a0at\u00a0https:\/\/ir.tyra.bio<\/a>. To participate via telephone, please register in advance at this\u00a0link<\/a>. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company’s website for at least 90 days.<\/p>\n

\n About Tyra Biosciences<\/b>\n <\/p>\n

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA’s in-house precision medicine platform, SN\u00c5P, enables rapid and precise drug design through iterative molecular SN\u00c5Pshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. TYRA’s expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA’s lead precision medicine stemming from SN\u00c5P, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4\/3-biased inhibitor for FGF19+\/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1\/2\/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, California. For more information, please visit www.tyra.bio<\/a>\u00a0and engage with TYRA on LinkedIn.<\/p>\n

\n Contact
<\/b>Amy Conrad
aconrad@tyra.bio<\/a><\/p>\n

\n

\n \"\"\n <\/p>\n<\/p><\/div>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026-302870004.html<\/a><\/p>\n

SOURCE Tyra Biosciences<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire CARLSBAD, Calif., Sept. 4, 2026 \/PRNewswire\/ —\u00a0Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC). Conference Call and Webcast Information TYRA is hosting a conference call and webcast on September 9, 2026, at 8:00 am ET. Participants may access a live webcast of the call and the associated slide presentation on the “For Investors” page of the TYRA … <\/p>\n

Continue reading “Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1000658","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CARLSBAD, Calif., Sept. 4, 2026 \/PRNewswire\/ —\u00a0Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC). Conference Call and Webcast Information TYRA is hosting a conference call and webcast on September 9, 2026, at 8:00 am ET. Participants may access a live webcast of the call and the associated slide presentation on the “For Investors” page of the TYRA … Continue reading "Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T12:17:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1290905\/Tyra-Logo.jpg?id=OA2927934\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026\",\"datePublished\":\"2026-09-04T12:17:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/\"},\"wordCount\":404,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1290905\\\/Tyra-Logo.jpg?id=OA2927934\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/\",\"name\":\"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1290905\\\/Tyra-Logo.jpg?id=OA2927934\",\"datePublished\":\"2026-09-04T12:17:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1290905\\\/Tyra-Logo.jpg?id=OA2927934\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1290905\\\/Tyra-Logo.jpg?id=OA2927934\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/","og_locale":"en_US","og_type":"article","og_title":"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 - Market Newsdesk","og_description":"PR Newswire CARLSBAD, Calif., Sept. 4, 2026 \/PRNewswire\/ —\u00a0Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC). Conference Call and Webcast Information TYRA is hosting a conference call and webcast on September 9, 2026, at 8:00 am ET. Participants may access a live webcast of the call and the associated slide presentation on the “For Investors” page of the TYRA … Continue reading \"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-04T12:17:08+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1290905\/Tyra-Logo.jpg?id=OA2927934","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026","datePublished":"2026-09-04T12:17:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/"},"wordCount":404,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1290905\/Tyra-Logo.jpg?id=OA2927934","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/","name":"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1290905\/Tyra-Logo.jpg?id=OA2927934","datePublished":"2026-09-04T12:17:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1290905\/Tyra-Logo.jpg?id=OA2927934","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1290905\/Tyra-Logo.jpg?id=OA2927934"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1000658"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000658\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1000658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1000658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1000658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}